AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Obesity treatment with a satiety promoting peptide

Summary: Paul David Berk, M.D.

Technology Benefits: This peptide is a natural hormone peptide. Already has natural biological activity in the gut and in significantly under-expressed in obese patients. Successfully reduces body weight by reducing food intake, eliminating adipocyte free fatty acid uptake rates in several models of obesity, including tissue samples from obese humans.Patent information:(WO2012051567)Tech Ventures Reference: IR 2723

Technology Application: Treatment of obesity, general weight control and appetite regulationTreatment of metabolic syndrome, insulin resistance, fatty liver disease, obesity related cardiomyopathy and other obesity-associated disorders. Detection of obesity or obesity-associated disordersDetection of an obesity classification based on message or protein expression profilingAn alternative treatment and/or complement to obesity surgery

Detailed Technology Description: Paul David Berk, M.D.

*Abstract: None

*Inquiry: Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR: 2723

*Principal Investigator

*Publications: *Walewski, JL et al. Spexin is a novel human peptide that reduces adipocyte uptake of long chain fatty acids and causes weight loss in rodents with diet-induced obesity. Obesity (Silver Spring). Feb, 2014.

Country/Region: USA

For more information, please click Here